



Synthesis and stereochemical determination of an antiparasitic pseudo-aminal type monoterpene indole alkaloid

Yoshihiko Noguchi^{1,2} · Tomoyasu Hirose^{1,2} · Aki Ishiyama^{1,2} · Masato Iwatsuki^{1,2} · Kazuhiko Otoguro¹ · Toshiaki Sunazuka^{1,2} · Satoshi Ōmura¹

Received: 25 April 2016 / Accepted: 14 May 2016 / Published online: 21 June 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract 5-Nor stemmadenine alkaloids, isolated from the genus *Tabernaemontana*, display a range of bioactivity. 16-Hydroxy-16,22-dihydroapparicine, the active component of an extract from the *Tabernaemontana* sp. (*dichotoma*, *elegans*, and *divaricate*), exhibited potent antimalarial activity, representing the first such report of the antimalarial property of 5-nor stemmadenine alkaloids. We, therefore, decided to attempt the total synthesis of the compound to explore its antimalarial activity and investigate structure and bioactivity relationships. As a result, we completed the first total synthesis of 16-hydroxy-16,22-dihydroapparicine, by combining a phosphine-mediated cascade reaction, diastereoselective nucleophilic addition of 2-acylindole or methylketone via a Felkin–Anh transition state, and chirality transferring intramolecular Michael addition. We also clarified the absolute stereochemistries of the compound. Furthermore, we evaluated the activity of the synthetic compound, as well as that of some intermediates, all of which showed weak activity against chloroquine-resistant *Plasmodium falciparum* (K1 strain) malaria parasites.

Keywords 5-Nor stemmadenine alkaloid · Antimalarial agent · Pseudo-aminal type structure · Iminophosphorane

mediated cascade reaction · Chirality transfer
intramolecular Michael reaction · Diastereoselective
1,2-addition using indole nucleophile

Introduction

Naturally occurring chemicals represent a treasure trove of compounds which hold promise as the seeds of discovery for drugs and medicines and which may facilitate the elucidation of structure and function investigations of bioactivity [1]. Ōmura's research group at the Kitasato Institute is a global pioneer in the search for bioactive agents that may be of use in developing drugs and medicines to fight to infection and combat tropical diseases (such as the filariases, malaria, trypanosomiasis, etc.), all originating from microbial metabolites. At present, 483 new compounds have been discovered, 26 of which have become useful, widely used agents in human and animal health, including the ground-breaking avermectins [2].


Malaria is one of the world's worst health and socioeconomic problems, causing widespread death, disease, disability, and economic loss. Infection arises when a protozoal parasite of the *Plasmodium* genus is transmitted to humans via the bites of blood-feeding mosquitoes. *Plasmodium falciparum* parasites cause the most deadly form of the disease, which can cause death in a few days, especially if cerebral malaria develops. Generally, most deaths occur in children under 5 years old, although deaths have been reduced markedly by recent global initiatives to tackle the disease [3–5]. Commonly used drugs to combat malaria include quinine, chloroquine, mefloquine, halofantrine, and sulfadoxine/pyrimethamine (Fig. 1). However, drug resistance in parasites has usually developed quickly, rendering many of these drugs useless, preventing

✉ Toshiaki Sunazuka
sunazuka@lisci.kitasato-u.ac.jp

✉ Satoshi Ōmura
omuras@insti.kitasato-u.ac.jp

¹ Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

² Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

Fig. 1 Therapeutic drugs for malaria**Table 1** Antimalarial activity and cytotoxicity of *Tabernaemontana dichotoma* extract

	IC ₅₀ (μg/mL)				
	Antimalarial activity		Cytotoxicity	Selectivity index (SI)	
	K1 ^a	FCR3 ^b	MRC-5	M/K ^c	M/F ^d
<i>Tabernaemontana dichotoma</i> MeOH extract	0.59	0.35	>25.0	>42.4	>71.4
Artemisinin	0.006	0.006	45.2	7528	7528

^a Chloroquine-resistant strain^b Chloroquine-sensitive strain^c MRC-5/K1^d MRC-5/FCR3

effective treatment and hindering disease elimination efforts. In 1972, Professor Tu Youyou discovered artemisinin to be the active ingredient in the plant *Artemisia annua*, which was commonly used in China to treat fever. Artemisinin derivatives became the most effective therapeutic drugs against malaria [6]. The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) for malaria treatment [7], a multidrug approach requiring the use of artemisinin together with other drugs to help offset the pace of drug resistance to artemisinin developing and spreading. ACTs are already compromised because the safety of artemisinin with regard to use during first trimester pregnancy is yet to be established and, worse, resistance to artemisinin derivatives developed almost immediately in locations along the Thai–Cambodian border [8–11]. Therefore, inexpensive and potent antimalarial drugs, especially those that have different modes of action, are urgently required on a probably continuing basis due to the ability of the malaria parasites to quickly develop drug resistance.

Many of the therapies currently in development use known antimalarial pharmacophores (e.g., aminoquinolines and/or peroxides), which have been chemically modified to overcome the failures of their predecessors [12]. Although these compounds have been important in the treatment of

malaria, it would be highly advantageous to discover chemotypes with novel action mechanisms [13]. However, despite important advances in our understanding of the *Plasmodium* genome, the identification and validation of new drug targets have been challenging [14–16].

16-Hydroxy-16,22-dihydroapparicine (**1**), a known 5-nor stemmadenine alkaloid, was identified at the Kitasato Institute as a main component of a leaf's MeOH extract from the plant *Tabernaemontana dichotoma*, which displayed antimalarial properties. The potent antimalarial activity of the complex leaf extract against chloroquine-resistant *Plasmodium falciparum* (K1 strain) parasites in vitro, and its moderate selectivity (against MRC-5 strain human cells) are summarized in Table 1. Natural compound **1** was originally isolated from a leaf of *Tabernaemontana dichotoma* in 1984 by the Verpoorte group [17] (Fig. 2). The relative structural determination of **1** was based on detailed NMR study, yet the absolute stereochemistry was not determined. As **1** has the potential to contain antimalarial activity, we decided to attempt the total synthesis of **1** to confirm its stereochemistry and investigate its antimalarial effect.

In this review, the total synthesis, stereochemical determination, and antimalarial activity of 16-hydroxy-16,22-dihydroapparicine are discussed [18, 19].

Fig. 2 Structure of (15*S*,16*S*)-16-hydroxy-16,22-dihydroapparicine (**1**)





Fig. 3 Structure of apparicine (**2**) and related compounds

Naturally occurring compound **1** has the same framework as Apparicine (**2**), the first 5-nor stemmadenine alkaloid discovered, which was isolated from *Aspidosperma dasycarpon* more than 45 years ago [20, 21] (Fig. 3). There are currently 22 known 5-nor stemmadenine alkaloid compounds [22–32], with the compounds exhibiting a wide range of biological activity, including being antimicrobial [33–35] and antibacterial (antituberculous) [32], as well as displaying opioid properties [36]. Consequently, these alkaloids are of considerable interest. The main structural feature of the alkaloids is the strained 1-azabicyclo[4.2.2]decane skeleton, including a single carbon connection, between the indole 3-position and aliphatic nitrogen moiety, which is a defining characteristic of these compounds. The relative stereochemistry of **2–5** has also been reported for conolidine (**6**), the completed asymmetric total synthesis being accomplished by Micalizio's group [37].

Proposed biosynthesis

The special architecture involved, embodying a 1-azabicyclo[4.2.2]decane, is probably the result of the C-5 tryptamine atom being excised from the alkaloid stemmadenine by a retro-Mannich reaction. Some *in vitro* transformations of stemmadenine-type to 5-nor stemmadenine-type alkaloids have provided further support for this biogenetic model, which the following summarizes.

Kutney and co-workers reported the biosynthesis of the 1-azabicyclo[4.2.2]decane structure in the 5-nor stemmadenine alkaloids 50 years ago, using incorporated radioisotope experiments on the plant *Aspidosperma pyrrolidum*. Later, Lim and co-workers [38] reported partial


synthesis of the *pseudo*-aminal type indole alkaloids, such as apparicine (**2**), using Potier's expected biomimetic oxidative transformation from pericine (**7**) (Scheme 1).

Synthesis studies


Due to their unique structure and potentially useful biological activity, the total synthesis of 5-nor stemmadenine alkaloids has been reported by Bennasar et al. [39, 40], Micalizio [37], and Takayama [41] (Scheme 2). In addition, synthetic work on the 1-azabicyclo[4.2.2]decane skeleton core has been published by Joule [42, 43] and Weinreb's group [44] (Scheme 3). A recent report of the total synthesis of (±)-apparicine (**2**) by Bennasar and co-workers [39, 40] detailed an approach which utilized an intramolecular Heck reaction. Micalizio and Takayama [37, 41] reported the total syntheses of conolidine (**6**), which could be derived from an iminium ion under intramolecular Mannich reaction. In addition, Micalizio and co-workers [37] clarified the absolute stereochemistry of **6**.

In 1977, Joule and co-workers [42, 43] reported the synthesis of apparicine, detailing an approach to **2** which utilizes an intramolecular Mannich cyclization to construct the 1-azabicyclo[4.2.2]decane skeleton. Weinreb's group [44] reported the construction of a 4-cyclic compound **17** using nitrosoalkene and indole in 2014.

Our synthetic approach used a distinctive reaction based on the hypothesis that the main structural feature of these alkaloids is the strained 1-azabicyclo[4.2.2]decane skeleton, including a single carbon connection between the indole 3-position and aliphatic nitrogen moiety, which is a gramine-type (or vinamidine-type) moiety (Fig. 4). This structure has a “push–pull” nature, which is stabilized by electron-donating or electron-withdrawing groups. For example, the aliphatic carbon–nitrogen bond of the gramine type (or vinamidine type) is easily cleaved by retro-Mannich reaction under acid [45], base [46–48], and thermal [49] conditions, and with various reagents (e.g., trialkylphosphine [50–55], Lewis acid [56], phthalimide [57], thiol [58, 59], and activated ester [60, 61]) to generate the indolinium cation. We, therefore, anticipated that the



Scheme 1 Biomimetic transformation







Scheme 2 Reported total synthesis of apparicine and conolidine

propendiamine moiety was an indicator of reactivity similar to the aminal, leading us to suppose the framework as a “*pseudo-aminal type structure*”.

To complete the total synthesis of (15*S**,16*S**)-16-hydroxy-16,22-dihydroapparicine (**1**), we designed a novel phosphineimine-mediated cascade reaction, without any isolated unstable intermediate (Scheme 4). The cascade reaction sequence was: (1) Staudinger reaction of an azide **21** with triphenylphosphine to generate phosphineimine

intermediate **20** [62]; (2) intramolecular N-allylation of phosphineimine transformed into aminophosphonium **19** [63–65]; (3) aza-Wittig reaction of **19** with formaldehyde; and (4) intramolecular Mannich reaction; nucleophilic attack might be performed from the indole 3-position to iminium cation **18**. We needed to solve two challenging issues. Firstly, the N-allylation of the phosphineimine group; phosphineimine has relatively high nucleophilicity, while the leaving group involves sufficient electrophilicity.

Joule's group*Weinreb's group***Scheme 3** Reported synthetic study of the 1-azabicyclo[4.2.2]decane skeleton**Fig. 4** Gramines (vinamidines) as versatile *pseudo*-aminal type compounds**Scheme 4** Designed novel phosphineimine-mediated cascade reaction

Secondly, the formation of iminium cation using the aminophosphonium salt; there was no reported generation of iminium cation using the aminophosphonium salt and aldehyde via the aza-Wittig reaction. We found a solitary instance of the aminophosphonium salt with excess DMF to generating formamidinium salt [66]. However, the


potential reactivity of the aminophosphonium salt has never been investigated. If we could overcome these challenges, an aminophosphonium salt (such as **19**) could become a useful reactant for the aza-Wittig reaction. The key precursor **21** could be prepared from diastereoselective methylation of 2-acylindole **22** with completion of the

C-16 stereochemistry outcome of the Felkin–Anh transition state [67–71] (Scheme 5). Compound **22** could be constructed with the indole nucleophile and azidoaldehyde **23**.


To construct the C-15 stereocenter, we envisaged a remote stereocontrolled Michael reaction [72] of the α,β -unsaturated carboxamide **25** with the crotonic acid derivative.

Synthesis of the azidoaldehyde **23** began from commercially available *cis*-butenediol, to afford (–)-**25** [73] (Scheme 6). With the Michael accepter in hand, we attempted the remote stereocontrolled Michael reaction of (–)-**25**, with only minor success, (–)-**25** appearing with no stereoselection and in low yield, along with γ -adduct as an undesired product. Subsequently, olefin isomerization afforded the unsaturated *E*-olefin **24** as a 1:1 diastereomixture (at C-15). Then, eight steps functionalization provided the azidoaldehyde (\pm)-**23** in 38 % overall yield.


With the azidoaldehyde (\pm)-**23** and the *N*-phenylsulfonyl indole **27** [74–81] in hand, we examined the nucleophilic addition, the hydroxyindole (\pm)-**28** being provided in 85 % yield as a single diastereomer (Scheme 7). Following the oxidation of (\pm)-**28** to obtain the (\pm)-ketoindole, the *N*-phenylsulfonyl and pivaloyl groups were subsequently removed under basic solvolysis to provide the hydroxyketoindole (\pm)-**22** in 87 % yield. Diastereoselective methylation of (\pm)-**22** converted it to dihydroxyindole (\pm)-**29** as a single diastereomer in excellent yield. The planar structure of (\pm)-**29** was confirmed by HMQC and HMBC studies. We expected the stereoselectivity outcome to be the Felkin–Anh transition state and so sought a suitable leaving group on the allyl alcohol. We eventually discovered a 3-nitropyridyl group [82, 83] as an efficient leaving group, allowing conversion of the 3-nitropyridinylation of (\pm)-**29** into the cascade reaction precursor



Scheme 5 Retrosynthetic analysis of key intermediate



Scheme 6 Synthesis of azidoaldehyde (**23**)



Scheme 7 Synthesis of proposed hydroxyapparine (**1**)

(±)-**21** in 93 % yield, using the process reported by Ballesteros and co-workers [84, 85]. We then attempted construction of the 1-azabicyclo[4.2.2]decane skeleton, including the *pseudo*-aminal moiety. The cascade reaction precursor (±)-**21**, with PPh₃ at 60 °C, generated iminophosphorane, the reaction mixture subsequently being acidified using AcOH for activation of the 3-nitropyridyl group. Finally, formaldehyde and PPTS were added to the reaction mixture to convert the iminophosphonium cation, followed by a Mannich reaction to furnish (±)-**1** in 88 % yield. The relative stereochemistry was confirmed by ROESY correlations (Fig. 5).

Structure determination

However, the spectral data of synthetic (±)-**1** did not agree with that of naturally occurring **1** [17]. In particular, analysis of synthetic (±)-**1**, showed a ROESY relationship between H-18 or H-19 and 16-Me. Consequently, the relative stereochemistry of synthetic (±)-**1** was determined to




Fig. 5 ROESY observations of synthetic (±)-(15S*,16S*)-**1**

be a 15S*,16S*-configuration. Data of synthetic (±)-(15S*,16S*)-**1** were then compared with naturally occurring compound (Table 2), with ¹H and ¹³C NMR indicating differences of chemical shift (differences of all positions are shown in the experiment section). In ¹H NMR, 16-Me and H-6 α,β signals were registered more than 0.20 ppm and, furthermore, the ¹³C signals of the piperidine ring were greatly shifted from those seen in natural occurring **1**. Therefore, we expected that the 16-Me group in naturally

Table 2 Comparison of the NMR data of synthetic (\pm)-(15*S**,16*S**)-16-hydroxy-16,22-dihydroapparicine (**1**) with those reported for the natural product

Position	¹ HNMR			¹³ CNMR		
	Synthetic (\pm)-(15 <i>S</i> *,16 <i>S</i> *)- 1 ^a δ_H (int., mult, <i>J</i> in Hz)	Reported 1 ^b δ_H (int., mult, <i>J</i> in Hz)	$\Delta\delta^c$	Synthetic (\pm)-(15 <i>S</i> *,16 <i>S</i> *)- 1 ^a δ_C	Reported 1 ^b δ_C	$\Delta\delta^c$
NH	8.30 (br s)	9.10 (br s)	−0.80	–	–	–
2	–	–	–	136.1	138.1	−2.0
3	3.04 (ddd, 14.0, 12.0, 7.0) 2.85 (dd, 14.0, 7.0)	2.89–2.95 (m)	–	46.8	48.4	−1.6
6	4.25 (d, 18.0) 4.58 (d, 18.0)	3.95 (d, 17.5) 4.73 (d, 17.5)	0.3 −0.15	53.4	50.4	3
7	–	–	–	109.4	107.3	2.1
8	–	–	–	127.9	129.9	−2.0
9	7.44 (d, 7.0)	7.46 (br d, 8.0)	−0.02	118.5	118.5	0
10	7.08 (ddd, 8.0, 7.0, 1.0)	7.18 (ddd, 8.0, 7.5, 1.0)	−0.10	119.2	119.2	0
11	7.20 (ddd, 8.0, 7.0, 1.0)	7.08 (ddd, 8.0, 7.5, 1.0)	0.12	122.6	122.3	−0.3
12	7.32 (ddd, 7.0, 2.0, 1.0)	7.33 (br d, 8.0)	−0.01	110.4	110.3	−0.1
13	–	–	–	135.3	135.2	0.1
14	1.87 (dddd, 14.0, 12.0, 7.0, 1.0) 2.22 (dddd, 14.0, 11.0, 7.0, 2.0)	2.01–2.22 (m)	–	25.0	23.4	1.6
15	3.35 (d, 7.0)	3.32 (dd, 3.5, 12.0)	0.02	44.0	43.2	0.8
16	–	–	–	76.2	74.5	1.7
18	1.75 (d, 8.6)	1.75 (ddd, 6.9, 2.5, 1.0)	0	13.7	13.8	−0.1
19	5.59 (br dq, 7.0, 1.0)	5.69 (q, 6.9)	−0.10	122.0	124.9	−2.9
20	–	–	–	136.1	134.5	1.6
21	3.79 (br d, 16.0) 3.64 (br dq, 16.0, 2.0)	3.66 (br d, 17.0) 3.58 (br d, 17.0)	0.13 0.06	55.1	53.2	1.9
22	1.56 (s)	1.73 (s)	−0.17	30.1	30.2	−0.1

^a Measured in CDCl₃ (¹H: 500 MHz, ¹³C: 125 MHz)

^b Measured in CDCl₃ (¹H: 300 MHz, ¹³C: 75 MHz)


^c $\Delta\delta$ ($\delta_{\text{Syn}} - \delta_{\text{Nat}}$)

occurring **1** was on the opposite face for the tri-substituted *exo*-cyclic olefin. Accordingly, the relative stereochemistry was anticipated to be the 15*S**,16*R**-configuration.

To confirm this consideration, we set about the synthesis of 15*S**,16*R**-isomer. The disputed stereocenter was prepared from ketoindole and methyl anion via the Felkin–Anh transition state. Therefore, the *R*-configuration could be constructed with methylketone (\pm)-**30** and indole nucleophile. We search and optimized nucleophilic addition using indole nucleophile. As a result, we found (*t*-butyldimethylsilyloxy)methyl (TBSOM) group [86–91] protected iodoindole as a suitable compound (Scheme 8). Hence, nucleophilic addition of **31** with (\pm)-**30** was converted into (\pm)-**32** in 97 % yield as a single diastereomer. The planar structure of (\pm)-**32** was confirmed by 2D NMR study. Subsequently, global deprotection of (\pm)-**32** obtained (\pm)-**33** in excellent yields. Following the same reaction sequence as the synthesis of (\pm)-(15*S**,16*S**)-**1** produced (\pm)-(15*S**,16*R**)-**1**. Characterization data

provided for synthetic (\pm)-(15*S**,16*R**)-**1** were fully consistent with the data for the naturally occurring compound reported by Verpoorte and co-workers [17] (Table 3). In addition, an NOE relationship was observed between H-14a and H-22 (i.e., 16-Me) (Fig. 6).

To clarify the cascade reaction mechanism, we attempted the experiment outlined in Scheme 9. At first, to provide the corresponding primary amine, a Staudinger reaction of (\pm)-**34** with PPh₃ was carried out under reflux condition to obtain the piperidine-indole (\pm)-**37**, without acidic activation of the 3-nitropyridinyl group. ESI mass-monitoring of the first reaction allowed phosphineimine **35** to be easily generated from (\pm)-**34** and PPh₃ without transformation into primary amine via solvolysis. In a time-dependent change, phosphineimine smoothly converted to the aminophosphonium cation **36**. Though the 3-nitropyridinyl group was a low electrophile, it was unnecessary for acidic activation. We inferred that the 1,3-allylic strain [92] was a key component, occurring via the tri-substituted



Scheme 8 Total synthesis of (±)-(15 S^* ,16 R^*)-1

Table 3 Comparison of the NMR data of synthetic (±)-(15 S^* ,16 R^*)-16-hydroxy-16,22-dihydroapparicine; (±)-(15 S^* ,16 R^*)-1 with those reported for the natural product

Position	Synthetic (±)-(15 S^* ,16 R^*)-1 ^a δ_H (int., mult, J in Hz)	Reported 1 ^b δ_H (int., mult, J in Hz)	$\Delta\delta^c$	Synthetic (±)-(15 S^* ,16 R^*)-1 ^a δ_C	Reported 1 ^b δ_C	$\Delta\delta^c$
NH	8.42 (br s)	9.10 (br s)	-0.68	-	-	-
2	-	-	-	138.2	138.1	0.1
3	2.89–2.98 (m)	2.89–2.95 (m)	0	48.4	48.4	0
6	4.77 (d, 17.2)	4.73 (d, 17.5)	0.04	50.3	50.4	-0.1
	3.96 (d, 17.2)	3.95 (d, 17.5)	0.01			
7	-	-	-	106.9	107.3	-0.4
8	-	-	-	128.6	129.9	-1.3
9	7.47 (d, 8.0)	7.46 (br d, 8.0)	0.01	118.5	118.5	0
10	7.18 (dd, 7.5, 7.5)	7.18 (ddd, 8.0, 7.5, 1.0)	0	119.2	119.2	0
11	7.08 (dd, 7.5, 7.5)	7.08 (ddd, 8.0, 7.5, 1.0)	0	122.4	122.3	0.1
12	7.31 (d, 8.0)	7.33 (br d, 8.0)	-0.02	110.4	110.3	0.1
13	-	-	-	135.2	135.2	0
14	2.17 (m)	2.01–2.22 (m)	-	23.2	23.4	0.2
	2.02 (m)					
15	3.31 (dd, 3.2, 11.7)	3.32 (dd, 3.5, 12.0)	-0.01	43.1	43.2	-0.1
16	-	-	-	74.5	74.5	0
18	1.75 (d, 8.6)	1.75 (ddd, 6.9, 2.5, 1.0)	0	13.8	13.8	0
19	5.67 (q, 6.9)	5.69 (q, 6.9)	-0.02	125.2	124.9	0.3
20	-	-	-	134.1	134.5	-0.4
21	3.70 (d, 17.2)	3.66 (br d, 17.0)	0.04	53.1	53.2	0.1
	3.52 (d, 16.6)	3.58 (br d, 17.0)	-0.06			
22	1.74 (s)	1.73 (s)	0.01	30.1	30.2	-0.1

^a Measured in CDCl₃ (¹H: 500 MHz, ¹³C: 125 MHz)

^b Measured in CDCl₃ (¹H: 300 MHz, ¹³C: 75 MHz)

^c $\Delta\delta$ ($\delta_{Syn} - \delta_{Nat}$)

olefin. Therefore, the 3-nitropyridinyl group was located within close proximity of the phosphineimine group. Subsequent intramolecular Mannich reaction of piperidine-





Fig. 6 NOE observations of synthetic (+)-(15 S^* ,16 R^*)-1


indole (\pm)-**37** provided (\pm)-(15 S^* ,16 R^*)-**1** in 43 % yield, using formaldehyde and PPTS. We subsequently expected that the aza-Wittig reaction of **36** with formaldehyde could assist in generating the iminium cation precursor **38** in a cascade reaction.

Asymmetric total synthesis of 16-hydroxy-16,22-dihydroapparicine

We achieved the total synthesis of racemic 16-hydroxy-16,22-dihydroapparicine (**1**) and determined the true relative stereochemistry of the naturally occurring compound. In the next stage, we established the absolute stereochemistry of **1**. In order to accomplish asymmetric total




Scheme 9 Stepwise synthesis of (\pm)-(15 S^* ,16 R^*)-1




LG = Leaving group, PG = Protecting group

Scheme 10 Asymmetric synthetic plan of (15 S ,16 R)-1



Scheme 11 Asymmetric synthesis of methylketone (+)-30



Scheme 12 End game of the total synthesis of (+)-(15S, 16R)-1

synthesis, we used the chiral methylketone **30** (Scheme 10), which could be supplied from azidobutyrolactone **39**, including the appropriate functional groups. If **39** formed acetylbutyrolactone **40**, its acetyl and ester moiety could be transformed into *E*-ethylidene and azido groups, respectively. Acetylbutyrolactone **40** was, therefore, our key intermediate, with synthetic manners for related compounds having already been reported by Smith's group and others [93–96]. We expected that **40** would involve a C-15 stereocenter being constructed by the intramolecular chirality transferring Michael reaction. We expected to perform via 5-*exo*-cyclization in the ketoester

41, which should be stereo-specifically constructed by the Baldwin rule [97] and Thorpe–Ingold effect [98, 99].


Synthesis of the optically pure tri-substituted **40** began from commercially available (–)-(*R*)-methyl lactate **42**, which, after with four steps of preparation, provided the ketoester (+)-**41** in excellent yield (Scheme 11). With the optically pure (+)-**41** in hand, we attempted the intramolecular chirality transferring Michael reaction [100–104]. Through extensive optimization, we found a suitable condition to provide (+)-**40** in 91 % yield as a single diastereomer, and assignment of the relative stereochemistry was derived from the coupling constants and

NOE correlation between α and γ protons. The key factor of the intramolecular chirality transferring Michael reaction was the solvent's effect; polar solvent was stabilized to the anticipated transition state. The acetyl group of (+)-**40** converted into the ethylidene moiety along with the separable *Z*-isomer. The tri-substituted olefin moiety was determined to be of *E*-configuration by NOE correlation. The configuration of the C-3 stereocenter of (–)-**43** was determined after simple modification; hydrogenation of (–)-**43** obtained a single diastereomer, and the stereochemistry was confirmed to be *S*-configuration by NOE and ROESY correlation. Compound (–)-**43** was transformed into primary alcohol **44** by stepwise preparation; at first, selective hydrolysis of the ethyl ester group under basic condition generated carboxylic acid, followed by the corresponding acid anhydride. The furnished carboxylic

anhydride was immediately reduced to the desired (–)-**44** in 82 % yield over the two steps [105, 106]. Subsequently, four steps functionalization provided the chiral methylketone (+)-**30** in excellent yield without racemization. The optical purity of the (+)-**30** (97 %ee) was confirmed by chiral HPLC analysis. The *R*-isomer of (–)-**30** was prepared in the same asymmetric synthetic manner from (–)-(*S*)-methyl lactate.

Finally, (+)-**32** was exposed to the same procedure using (\pm)-(15*S**,16*R**)-16-hydroxy-16,22-dihydroap-*paricine* **1** (Scheme 12). The cascade reaction precursor (–)-**36** underwent the same cascade reaction condition as that for the synthesis of (\pm)-(15*S**,16*S**)-**1**, (\pm)-(15*S**,16*R**)-**1** to give (+)-(15*S*,16*R*)-**1**. Characterization data proved that synthetic (+)-(15*S*,16*R*)-**1** was fully consistent with the data for the natural compound, as reported

Table 4 Antimalarial activity of synthetic **1** and some intermediate compounds



	IC ₅₀ (μg/mL)				
	Antimalarial activity		Cytotoxicity	Selectivity index (SI)	
	K1 ^a	FCR3 ^b	MRC-5	M/K ^c	M/F ^d
<i>Tabernaemontana</i> leaf extract	0.59	0.35	>25.0	>42.4	>71.4
Synthetic (\pm)-(15 <i>S</i> *,16 <i>S</i> *)- 1	>12.5	ND	33.3	>2.7	–
Synthetic (+)-(15 <i>S</i> ,16 <i>R</i>)- 1	9.00	8.37	51.2	5.7	6.1
Synthetic (–)- 1	10.87	ND	75.2	6.9	–
(–)-(15 <i>S</i> ,16 <i>R</i>)- 32	>12.5	>12.5	ND	–	–
(–)-(15 <i>S</i> ,16 <i>R</i>)- 39	9.38	>12.5	54.0	5.8	<4.3
(–)-(15 <i>S</i> ,16 <i>R</i>)- 33	7.58	7.17	17.8	2.3	2.5
(–)-(15 <i>S</i> ,16 <i>R</i>)- 34	8.04	>12.5	>100.0	>12.4	8.0
(\pm)-(15 <i>S</i> ,16 <i>R</i>)- 37	8.98	>12.5	40.8	4.5	<3.3
Artemisinin	0.006	0.006	45.2	7528	7528

^a Chloroquine-resistant strain

^b Chloroquine-sensitive strain

^c MRC-5/K1

^d MRC-5/FCR3

by Verpoorte and co-workers [17]. The optical rotation of synthetic (+)-(15*S*,16*R*)-**1**, $[\alpha]_{\text{D}}^{26} +112.2$ (*c* 0.9, EtOH), compared well with the values reported for the natural sample, $[\alpha]_{\text{D}}^{20} +129$ (*c* 0.1, EtOH), and the optical rotation of synthetic (–)-(15*R*,16*S*)-**1**, $[\alpha]_{\text{D}}^{26} -104.2$ (*c* 0.1, EtOH), was prepared in an asymmetric synthetic manner. In addition, an NOE relationship was observed between H-14a and H-22 (i.e., 16-Me). Therefore, the C-16 stereochemistry was determined to be the *R*-configuration.

Biological activity

Naturally occurring and synthetic compounds were tested for antimalarial activity against *Plasmodium falciparum* parasites (chloroquine-resistant K1 strain and chloroquine-susceptible FCR3 strain) and for cytotoxicity (against human MCR-5 cells) [107–109], in comparison with the first-line antimalarial artemisinin.

The in vitro antimalarial activities and cytotoxicities of the naturally occurring and synthetic compounds are summarized in Table 1. As shown in Table 4, *Tabernaemontana* leaf extract (which includes (+)-(15*S*,16*R*)-16-hydroxy-16,22-dihydroapparicine) showed activity against both the chloroquine-resistant K1 strain and the chloroquine-sensitive FCR3 strains of *Plasmodium falciparum* (approximately 78-fold less potent than artemisinin, and with synthetic (±)-(15*S**,16*S**)-**1** having no measurable impact on chloroquine-susceptible parasites). Synthetic (±)-(15*S**,16*S**)-**1**, (+)-(15*S*,16*R*)-**1**, (–)-**1** displayed moderate to weak antimalarial activity (in the range of 9.0 to >12.5 μg/mL), while synthetic (–)-**1** and intermediaries showed minimal impact (7.17 to >12.5 μg/mL). The cytotoxicities against human cells of all synthetic compounds were weak (IC₅₀ of 17–75 μg/mL), on average similar to that of artemisinin.

The IC₅₀ value of synthetic (+)-(15*S*,16*R*)-**1** proved to be significantly lower than the leaf extract containing naturally occurring (+)-(15*S*,16*R*)-16-hydroxy-16,22-dihydroapparicine.

Conclusion

We achieved the first total synthesis of (+)-(15*S*,16*R*)-16-hydroxy-16,22-dihydroapparicine (**1**) and the (–)-enantiomer and determined the absolute stereochemistry of naturally occurring **1**. The synthesis involved a novel cascade reaction for efficient construction of the 1-azabicyclo[4.2.2]decane, including a *pseudo*-aminal moiety, via a Staudinger reaction, N-allylation, aza-Wittig reaction, and Mannich reaction. In addition, we developed a new method using diastereoselective 1,2-addition of

methylketone, using *N*-TBSOM protecting the indole nucleophile and intramolecular chirality transferring Michael reaction with neighboring group participation. In particular, intramolecular chirality transferring Michael reaction proved to be a useful method for synthesis of the chiral tri-substituted butyrolactone. We established an effective enantioselective synthetic route for the production of *pseudo*-aminal alkaloids.

Synthetic (+)-(15*S*,16*R*)-**1** exhibited moderate/weak antimalarial activity against chloroquine-resistant *Plasmodium falciparum* parasites and there is a possibility that the structurally unique compounds may be useful for the development of novel antimalarial drug candidates.

Acknowledgments This work was supported by a grant for the 21st Century COE Program; a Grant-in-Aid for Young Scientists (22790017) to T.H. from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); and a Kitasato University Research Grant for Young Researchers to T.H. We also thank Dr. Kenichiro Nagai and Ms. Noriko Sato (School of Pharmacy, Kitasato University) for their contributions. We are grateful to Dr. Toh-Seok Kam (University of Malaya) for providing an authentic natural sample of 16-hydroxy-16,22-dihydroapparicine.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ōmura S (1992) The search for bioactive compounds from microorganisms. Brock/Springer series in contemporary biosciences. Springer-Verlag, New York
2. Ōmura S (2015) Splendid gifts from microorganisms, 5th edn. The Kitasato Institute, Tokyo
3. Ishiyama A, Iwatsuki M, Namatame M, Nishihara-Tsukashima A, Sunazuka T, Takahashi Y, Ōmura S, Otoguro K (2011) Borrelidin, a potent antimalarial: stage-specific inhibition profile of synchronized cultures of *Plasmodium falciparum*. *J Antibiot (Tokyo)* 64:381–384
4. World Health Organization (WHO) (2014) World malaria report 2014. Available online at: http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/. Accessed 1 Apr 2016
5. Ridley RG (2002) Medical need, scientific opportunity and the drive for antimalarial drugs. *Nature* 415:686–693
6. Greenwood BM, Fidock DA, Kyle DE, Kappe SHI, Alonso PL, Collins FH, Duffy PE (2008) Malaria: progress, perils, and prospects for eradication. *J Clin Invest* 118:1266–1276
7. Eastman RT, Fidock DA (2009) Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. *Nat Rev Microbiol* 7:864–874
8. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Arie F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ (2009) Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 361:455–467

9. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM; Artemisinin Resistance in Cambodia I (ARC1) Study Consortium (2008) Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* 359:2619–2620
10. White NJ (2008) Qinghaosu (artemisinin): the price of success. *Science* 320:330–334
11. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R (2007) Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. *Lancet Infect Dis* 7:136–144
12. Olliaro P, Wells TN (2009) The global portfolio of new antimalarial medicines under development. *Clin Pharmacol Ther* 85:584–595
13. Wells TN, Alonso PL, Gutteridge WE (2009) New medicines to improve control and contribute to the eradication of malaria. *Nat Rev Drug Discov* 8:879–891
14. Rottmann M, McNamara C, Yeung BKS, Lee MCS, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT (2010) Spiroindolones, a potent compound class for the treatment of Malaria. *Science* 329:1175–1180
15. Winzeler EA (2008) Malaria research in the post-genomic era. *Nature* 455:751–756
16. Ioset JR (2008) Natural products for neglected diseases: a review. *Curr Org Chem* 12:643–666
17. Perera P, van Beek TA, Verpoorte R (1984) 16(*S*)-Hydroxy-16,22-dihydroapparicine, a new alkaloid from the leaves of *Tabernaemontana dichotoma*. *J Nat Prod* 47:835–838
18. Noguchi Y, Hirose T, Furuya Y, Ishiyama A, Otoguro K, Ōmura S, Sunazuka T (2012) The first total synthesis and reassignment of the relative stereochemistry of 16-hydroxy-16,22-dihydroapparicine. *Tetrahedron Lett* 53:1802–1807
19. Hirose T, Noguchi Y, Furuya Y, Ishiyama A, Iwatsuki M, Otoguro K, Ōmura S, Sunazuka T (2013) Structure determination and total synthesis of (+)-16-hydroxy-16,22-dihydroapparicine. *Chem Eur J* 19:10741–10750
20. Gilbert B, Duarte AP, Nakagawa Y, Joule JA, Flores SE, Aguayo Brissolese J, Campello J, Carrazzoni EP, Owellen RJ, Blossey EC, Brown KS Jr, Djerassi C (1965) Alkaloid studies. L. The alkaloids of twelve *Aspidosperma* species. *Tetrahedron* 21:1141–1166
21. Joule JA, Monteiro H, Durham LJ, Gilbert B, Djerassi C (1965) Alkaloid studies. 48. The structure of apparicine, a novel *Aspidosperma* alkaloid. *J Chem Soc Perkin I* 4773–4780
22. Akhter L, Brown RT, Moorcroft D (1978) 10-Hydroxy- and 10-methoxyapparicine: two new alkaloids from *Ochrosia oppositifolia*. *Tetrahedron Lett* 19:4137–4140
23. Atta-ur-Rahman, Muzaffar A (1985) The isolation and structure of ervaticine, a new indole alkaloid from *Ervatamia coronaria*. *Heterocycles* 23:2975–2978
24. Kam TS, Pang HS, Choo YM, Komiyama K (2004) Biologically active ibogan and vallesamine derivatives from *Tabernaemontana divaricata*. *Chem Biodivers* 1:646–656
25. Michel S, Tillequin F, Koch M (1986) Brafouédine et Iso-brafouédine: nouveaux alcaloïdes indoliques mineurs de *Strychnos dinklagei*. *J Nat Prod* 49:452–455
26. Pawelka KH, Stöckigt J, Danieli B (1986) Epchrosine—a new indole alkaloid isolated from plant cell cultures of *Ochrosia elliptica* Labill. *Plant Cell Rep* 5:147–149
27. Walser A, Djerassi C (1964) Alkaloid-studien XLIX die strukturen von Vallesamin und *O*-acetyl-vallesamin. *Helv Chim Acta* 47:2072–2086
28. Atta-ur-Rahman, Alvi KA, Abbas SA, Voelter W (1987) Isolation of 19,20-*Z*-vallesamine and 19,20-*E*-vallesamine from *Alstonia scholaris*. *Heterocycles* 26:413–419
29. Zeches M, Ravao T, Richard B, Massiot G, Le Men-Olivier L, Verpoorte R (1987) Some new vallesamine-type alkaloids. *J Nat Prod* 50:714–720
30. Yamauchi T, Abe F, Padolina WG, Dayrit FM (1990) Alkaloids from leaves and bark of *Alstonia scholaris* in the Philippines. *Phytochemistry* 29:3321–3325
31. Ku WF, Tan SJ, Low YY, Komiyama K, Kam TS (2011) Angustilobine and andranginine type indole alkaloids and an uleine-*secovall*esamine bisindole alkaloid from *Alstonia angustiloba*. *Phytochemistry* 72:2212–2218
32. Macabeo APG, Krohn K, Gehle D, Read RW, Brophy JJ, Cordell GA, Franzblau SG, Aguinaldo AM (2005) Indole alkaloids from the leaves of Philippine *Alstonia scholaris*. *Phytochemistry* 66:1158–1162
33. van Beek TA, Deelder AM, Verpoorte R, Svendsen AB (1984) Antimicrobial, anti-moebic and antiviral screening of some *Tabernaemontana* species. *Planta Med* 50:180–185
34. van Beek TA, Verpoorte R, Svendsen AB, Fokkens R (1985) Antimicrobially active alkaloids from *Tabernaemontana chippii*. *J Nat Prod* 48:400–423
35. van der Heijden R, Brouwer RL, Verpoorte R, van Beek TA, Harkes PAA, Svendsen AB (1986) Indole alkaloids from *Tabernaemontana elegans*. *Planta Med* 52:144–147
36. Ingkaninan K, Ijzerman AP, Taesotikul T, Verpoorte R (1999) Isolation of opioid-active compounds from *Tabernaemontana pachysiphon* leaves. *J Pharm Pharmacol* 51:1441–1446
37. Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC (2011) Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. *Nat Chem* 3:449–453
38. Lim KH, Low YY, Kam TS (2006) Biomimetic oxidative transformations of pericine: partial synthesis of apparicine and valparicine, a new pentacyclic indole alkaloid from *Kopsia*. *Tetrahedron Lett* 47:5037–5039
39. Bannasar ML, Zulaica E, Solé D, Alonso S (2009) The first total synthesis of (±)-apparicine. *Chem Commun* (23):3372–3374
40. Bannasar ML, Zulaica E, Solé D, Roca T, García-Díaz D, Alonso S (2009) Total synthesis of the bridged indole alkaloid apparicine. *J Org Chem* 74:8359–8368
41. Takanashi N, Suzuki K, Kitajima M, Takayama H (2016) Total synthesis of conolidine and apparicine. *Tetrahedron Lett* 57:375–378
42. Scopes DIC, Allen MS, Hignett GJ, Wilson NDV, Harris M, Joule JA (1977) A synthetic approach to the indole alkaloid apparicine. Synthesis of the ring skeleton. *J Chem Soc Perkin Trans I* (21):2376–2385
43. Kettle JG, Roberts D, Joule JA (2010) Synthesis of 1,2,3,4,5,7-hexahydro-6*H*-azocino[4,3-*b*]indol-6-ones as intermediates for the synthesis of apparicine. *Heterocycles* 82:349–370
44. Chauhan PS, Weinreb SM (2014) Convergent approach to the tetracyclic core of the apparicine class of indole alkaloids via a key intermolecular nitrosoalkene conjugate addition. *J Org Chem* 79:6389–6393
45. Martin CL, Nakamura S, Otte R, Overman LE (2011) Total synthesis of (+)-condylocarpine, (+)-isocondylocarpine, and (+)-tubotaiwine. *Org Lett* 13:138–141
46. Hurt CR, Lin R, Rapoport H (1999) Enantiospecific synthesis of (*R*)-4-amino-5-oxo-1,3,4,5-tetrahydrobenz[*cd*]indole, an advanced intermediate containing the tricyclic core of the ergots. *J Org Chem* 64:225–233
47. Hart DJ, Magomedov N (1999) Spiroquinazoline support studies: new cascade reactions based on the Morin rearrangement. *J Org Chem* 64:2990–2991
48. Wada Y, Nagasaki H, Tokuda M, Orito K (2007) Synthesis of *N*-protected staurosporinones. *J Org Chem* 72:2008–2014

49. Diker K, Döéde Maindreville M, Royer D, Provost FL, Lévy J (1999) The gramine route to the Diels–Alder adducts of indolo-2,3-quinodimethanes. *Tetrahedron Lett* 40:7463–7467
50. Somei M, Karasawa Y, Kaneko C (1981) Selective monoalkylation of carbon nucleophiles with gramine. *Heterocycles* 16:941–949
51. Freed JD, Hart DJ, Magomedov NA (2001) Trapping of the putative cationic intermediate in the Morin rearrangement with carbon nucleophiles. *J Org Chem* 66:839–852
52. Low KH, Magomedov NA (2005) Phosphine-mediated coupling of gramines with aldehydes: a remarkably simple synthesis of 3-vinylindoles. *Org Lett* 7:2003–2005
53. Grubbs AW, Artman GD 3rd, Tsukamoto S, Williams RM (2007) A concise total synthesis of the notoamides C and D. *Angew Chem Int Ed Engl* 46:2257–2261
54. Artman GD 3rd, Grubbs AW, Williams RM (2007) Concise, asymmetric, stereocontrolled total synthesis of stephacidins A, B and notoamide B. *J Am Chem Soc* 129:6336–6342
55. Dubey R, Olenyuk B (2010) Direct organocatalytic coupling of carboxylated piperazine-2,5-diones with indoles through conjugate addition of carbon nucleophiles to indolenine intermediates. *Tetrahedron Lett* 51:609–612
56. de la Herrán G, Segura A, Csáky AG (2007) Benzylic substitution of gramines with boronic acids and rhodium or iridium catalysts. *Org Lett* 9:961–964
57. Csomós P, Fodor L, Sohár P, Bernáth G (2005) Synthesis of thiazino[6,5-b]indole derivatives, analogues of the phytoalexin cyclobrassinin. A new method for preparation of 3-aminomethylindole. *Tetrahedron* 61:9257–9262
58. Kennedy AR, Taday MH, Rainier JD (2001) The use of sulfur ylides in the synthesis of substituted indoles. *Org Lett* 3:2407–2409
59. Nishimura T, Yamada K, Takebe T, Yokoshima S, Fukuyama T (2008) (1-Nosyl-5-nitroindol-3-yl)methyl ester: a novel protective group for carboxylic acids. *Org Lett* 10:2601–2604
60. Shinohara H, Fukuda T, Iwao M (1999) A formal synthesis of optically active clavicipitic acids, unusual azepinoindole-type ergot alkaloids. *Tetrahedron* 55:10989–11000
61. Jones DT, Artman GD 3rd, Williams RM (2007) Coupling of activated esters to gramines in the presence of ethyl propiolate under mild conditions. *Tetrahedron Lett* 48:1291–1294
62. Staudinger H, Meyer J (1919) Über neue organische Phosphorverbindungen III. Phosphinmethylenderivate und Phosphinimine. *Helv Chim Acta* 2:635–646
63. Zimmer H, Singh G (1963) Synthesis of some triphenylphosphinalkylimines and mono- and dialkylaminotriphenylphosphonium halides. *J Org Chem* 28:483–486
64. Zimmer H, Jayawant M, Gutsch P (1970) Synthesis of secondary amines via triphenylphosphine imines. *J Org Chem* 35:2826–2828
65. Briggs EM, Brown GW, Jiricny J, Meidine MF (1980) Synthetic uses of iminophosphoranes. Monoalkylation of primary aromatic amines. *Synthesis* 1980:295–296
66. Frøyen P, Skramstad J (1998) Phosphorus in organic synthesis. The Tanigawa reaction revisited as a method for converting alcohols to tertiary amines. *Tetrahedron Lett* 39:6387–6390
67. Chérest M, Felkin H, Prudent N (1968) Torsional strain involving partial bonds. The stereochemistry of the lithium aluminium hydride reduction of some simple open-chain ketones. *Tetrahedron Lett* 9:2199–2204
68. Anh NT (1980) Regio- and stereo-selectivities in some nucleophilic reactions. *Top Curr Chem* 88:145–162
69. Anh NT, Eisenstein O (1977) Theoretical interpretation of 1–2 asymmetric induction-importance of anti-periplanarity. *Nouv J Chim* 1:61–70
70. Anh NT, Eisenstein O (1976) Induction asymétrique 1–2: comparaison ab initio des modèles de cram, de cornforth, de Karabatsos et de felkin. *Tetrahedron Lett* 17:155–158
71. Mengel A, Reiser O (1999) Around and beyond Cram’s rule. *Chem Rev* 99:1191–1224
72. Dambacher J, Anness R, Pollock P, Bergdahl M (2004) Highly diastereoselective conjugate additions of monoorganocopper reagents to chiral imides. *Tetrahedron* 60:2097–2110
73. Martinelli MJ (1990) Asymmetric Diels–Alder reaction with γ -functionalized α,β -unsaturated chiral *N*-acyloxazolidinones: synthesis of (+)-5-145. *J Org Chem* 55:5065–5073
74. Sundberg RJ, Russell HF (1973) Syntheses with *N*-protected 2-lithioindoles. *J Org Chem* 38:3324–3330
75. Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, Heidel F, Fischer T, Stocking C, Elz S, Böhmer FD, Dove S (2006) Novel bis(1*H*-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. *J Med Chem* 49:3101–3115
76. Naka H, Akagi Y, Yamada K, Imahori T, Kasahara T, Kondo Y (2007) Fluorous synthesis of Yuehchukene by α -lithiation of perfluoroalkyl-tagged 1-(arylsulfonyl)indole with mesityl-lithium. *Eur J Org Chem* (28):4635–4637
77. Mahboobi S, Uecker A, Cénac C, Sellmer A, Eichhorn E, Elz S, Böhmer FD, Dove S (2007) Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[*b*]furan-2-yl)methanones. *Bioorg Med Chem* 15:2187–2197
78. Bourderieux A, Kassis P, Mérou JY, Routier S (2008) Synthesis of new fused and substituted benzo and pyrido carbazoles via C-2 (het)arylindoles. *Tetrahedron* 64:11012–11019
79. So CM, Yeung CC, Lau CP, Kwong FY (2008) A new family of tunable indolylphosphine ligands by one-pot assembly and their applications in Suzuki–Miyaura coupling of aryl chlorides. *J Org Chem* 73:7803–7806
80. Noguchi-Yachide T, Tetsuhashi M, Aoyama H, Hashimoto Y (2009) Enhancement of chemically-induced HL-60 cell differentiation by 3,3'-diindolylmethane derivatives. *Chem Pharm Bull* 57:536–540
81. Denton JR (2010) One-pot desulfonylative alkylation of *N*-sulfonyl azacycles using alkoxides generated by phase-transfer catalysis. *Synthesis* (5):775–782
82. Yasukochi T, Inaba C, Fukase K, Kusumoto S (1999) Nitropyridyl glycosides: new glycosyl donors for enzymatic transglycosylation. *Tetrahedron Lett* 40:6585–6589
83. Yasukochi T, Fukase K, Kusumoto S (1999) 3-Nitro-2-pyridyl glycoside as donor for chemical glycosylation and its application to chemoenzymatic synthesis of oligosaccharide. *Tetrahedron Lett* 40:6591–6593
84. Ballesteros P, Claramunt RM (1987) Study of the catalytic properties of tris(3,6-dioxahexyl) amine (TDA-1) in heteroaromatic nucleophilic substitution of chloropyridines and their *n*-oxides. *Tetrahedron* 43:2557–2564
85. Nakano M, Kikuchi W, Matsuo JI, Mukaiyama T (2001) An efficient method for the *p*-methoxybenzylation of hydroxy group with 2-(4-methoxybenzyloxy)-3-nitropyridine. *Chem Lett* 30:424–425
86. Benneche T, Gundersen LL, Undheim K (1988) (*tert*-Butyldimethylsilyloxy)methyl chloride: synthesis and use as *N*-protecting group in pyrimidinones. *Acta Chem Scand B* 42:384–389
87. Gundersen LL, Benneche T, Undheim K (1989) Chloromethoxysilanes as protecting reagents for sterically hindered alcohols. *Acta Chem Scand* 43:706–709
88. Pitsch S, Weiss PA, Wu X, Ackermann D, Honegger T (1999) Fast and reliable automated synthesis of RNA and partially 2'-*O*-protected precursors ('caged RNA') based on two novel,

- orthogonal 2'-*O*-protecting groups. *Helv Chim Acta* 82:1753–1761
89. Pitsch S, Weiss PA, Jenny L, Stutz A, Wu X (2001) Reliable chemical synthesis of oligoribonucleotides (RNA) with 2'-*O*-[(triisopropylsilyl)oxy]methyl(2'-*O*-tom)-protected phosphoramidites. *Helv Chim Acta* 84:3773–3795
90. Zajac MA, Vedejs E (2004) A synthesis of the diazamide heteroaromatic biaryl macrocycle/hemiaminal core. *Org Lett* 6:237–240
91. Attaluri S, Bonala RR, Yang IY, Lukin MA, Wen Y, Grollman AP, Moriya M, Iden CR, Johnson F (2010) DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. *Nucleic Acid Res* 38:339–352
92. Hoffmann RW (1989) Allylic 1,3-strain as a controlling factor in stereoselective transformations. *Chem Rev* 89:1841–1860
93. Smith AB III, Sestelo JP, Dormer PG (1995) Total synthesis of (–)-furaquinocin C. *J Am Chem Soc* 117:10755–10756
94. Sestelo JP, Dormer PG (2000) A highly efficient synthetic route to (–)-furaquinocin C. *Heterocycles* 52:1315–1328
95. Greatrex BW, Kimber MC, Taylor DK, Fallon G, Tiekink ER (2002) 1,2-Dioxines as masked cis γ -hydroxy enones and their versatility in the synthesis of highly substituted γ -lactones. *J Org Chem* 67:5307–5314
96. Peña-López M, Martínez MM, Sarandeses LA, Pérez Sestelo J (2009) Total synthesis of (+)-neomarinone. *Chem Eur J* 15:910–916
97. Baldwin JE (1976) Rules for ring closure. *J Chem Soc Chem Commun* (18):734–736
98. Jung ME, Gervay J (1989) Solvent effects in intramolecular Diels–Alder reactions of 2-furfuryl methyl fumarates: evidence for a polar transition state. *J Am Chem Soc* 111:5469–5470
99. Yorimitsu H, Nakamura T, Shinokubo H, Oshima K, Omoto K, Fujimoto H (2000) Powerful solvent effect of water in radical reaction: triethylborane-induced atom-transfer radical cyclization in water. *J Am Chem Soc* 122:11041–11047
100. Li TT, Wu YL (1988) An approach to forskolin an efficient synthesis of a tricyclic lactone intermediate. *Tetrahedron Lett* 29:4039–4040
101. Somoza C, Darias J, Rúveda EA (1989) Intramolecular Michael–aldol condensation approach to the construction of advanced intermediates in the synthesis of forskolin. *J Org Chem* 54:1539–1543
102. Little RD, Masjedizadeh MR, Wallquist O, McLoughlin JJ (1995) The intramolecular Michael reaction. *Org React* 47:315–552
103. Bacigaluppo JA, Colombo MI, Preite MD, Zinczuk J, Rúveda EA (1996) The Michael–aldol condensation approach to the construction of key intermediates in the synthesis of nimbolide and nagilactone A. *Synth Commun* 26:2737–2749
104. Uchida K, Ishigami K, Watanabe H, Kitahara T (2007) Synthesis of an insecticidal tetrahydroisocoumarin, (3*R*,4*S*,4*aR*)-4,8-dihydroxy-3-methyl-3,4,4*a*,5-tetrahydro-1*H*-2-benzopyran-1-one. *Tetrahedron* 63:1281–1287
105. Crow JR, Thomson RJ, Mander LN (2006) Synthesis and confirmation of structure for the gibberellin GA₁₃₁ (18-hydroxy-GA₄). *Org Biomol Chem* 4:2532–2544
106. Lainchbury MD, Medley MI, Taylor PM, Hirst P, Dohle W, Booker-Milburn KI (2008) A protecting group free synthesis of (±)-neostenine via the [5 + 2] photocycloaddition of malimides. *J Org Chem* 73:6497–6505
107. Otoguro K, Kohana A, Manabe C, Ishiyama A, Ui H, Shiomi K, Yamada H, Ōmura S (2001) Potent antimalarial activities of polyether antibiotic, X-206. *J Antibiot* 54:658–663
108. Otoguro K, Ishiyama A, Ui H, Kobayashi M, Manabe C, Yan G, Takahashi Y, Tanaka H, Yamada H, Ōmura S (2002) In vitro and in vivo antimalarial activities of the monoglycoside polyether antibiotic, K-41 against drug resistant strains of *Plasmodia*. *J Antibiot* 55:832–834
109. Iwatsuki M, Takada S, Mori M, Ishiyama A, Namatame M, Nishihara-Tsukashima A, Nonaka K, Masuma R, Otoguro K, Shiomi K, Ōmura S (2011) In vitro and in vivo antimalarial activity of puberulic acid and its new analogs, viticolins A–C, produced by *Penicillium* sp. FKI-4410. *J Antibiot* 64:183–188